150 related articles for article (PubMed ID: 16211304)
1. Identification of reproducible low mass SELDI protein profiles specific to cisplatin resistance in human ovarian cancer cells.
Britten RA; Hardy C; Vlahou A; Gregory B; Giri PS; Drake R
Oncol Rep; 2005 Nov; 14(5):1323-30. PubMed ID: 16211304
[TBL] [Abstract][Full Text] [Related]
2. [Proteomic analysis of human ovarian cancer cell lines and their platinum-resistant clones].
Yan XD; Pan LY
Zhonghua Fu Chan Ke Za Zhi; 2006 Sep; 41(9):584-7. PubMed ID: 17181965
[TBL] [Abstract][Full Text] [Related]
3. Identification of platinum-resistance associated proteins through proteomic analysis of human ovarian cancer cells and their platinum-resistant sublines.
Yan XD; Pan LY; Yuan Y; Lang JH; Mao N
J Proteome Res; 2007 Feb; 6(2):772-80. PubMed ID: 17269733
[TBL] [Abstract][Full Text] [Related]
4. Novel mechanisms of platinum drug resistance identified in cells selected for resistance to JM118 the active metabolite of satraplatin.
Samimi G; Kishimoto S; Manorek G; Breaux JK; Howell SB
Cancer Chemother Pharmacol; 2007 Feb; 59(3):301-12. PubMed ID: 16770583
[TBL] [Abstract][Full Text] [Related]
5. The use of laser microdissection and SELDI-TOF MS in ovarian cancer tissue to identify protein profiles.
Cadron I; Van Gorp T; Amant F; Vergote I; Moerman P; Waelkens E; Daemen A; Van De Plas R; De Moor B; Zeillinger R
Anticancer Res; 2009 Apr; 29(4):1039-45. PubMed ID: 19414343
[TBL] [Abstract][Full Text] [Related]
6. Comparative proteomic analysis of cisplatin sensitive IGROV1 ovarian carcinoma cell line and its resistant counterpart IGROV1-R10.
Le Moguen K; Lincet H; Deslandes E; Hubert-Roux M; Lange C; Poulain L; Gauduchon P; Baudin B
Proteomics; 2006 Oct; 6(19):5183-92. PubMed ID: 16941573
[TBL] [Abstract][Full Text] [Related]
7. Ubiquitous induction of resistance to platinum drugs in human ovarian, cervical, germ-cell and lung carcinoma tumor cells overexpressing isoforms 1 and 2 of dihydrodiol dehydrogenase.
Deng HB; Adikari M; Parekh HK; Simpkins H
Cancer Chemother Pharmacol; 2004 Oct; 54(4):301-7. PubMed ID: 15138708
[TBL] [Abstract][Full Text] [Related]
8. Immune modulator CD70 as a potential cisplatin resistance predictive marker in ovarian cancer.
Aggarwal S; He T; Fitzhugh W; Rosenthal K; Feild B; Heidbrink J; Mesmer D; Ruben SM; Moore PA
Gynecol Oncol; 2009 Dec; 115(3):430-7. PubMed ID: 19800108
[TBL] [Abstract][Full Text] [Related]
9. A proteomic kinetic analysis of IGROV1 ovarian carcinoma cell line response to cisplatin treatment.
Le Moguen K; Lincet H; Marcelo P; Lemoisson E; Heutte N; Duval M; Poulain L; Vinh J; Gauduchon P; Baudin B
Proteomics; 2007 Nov; 7(22):4090-101. PubMed ID: 17994630
[TBL] [Abstract][Full Text] [Related]
10. Annexin XI is associated with cisplatin resistance and related to tumor recurrence in ovarian cancer patients.
Song J; Shih IeM; Salani R; Chan DW; Zhang Z
Clin Cancer Res; 2007 Nov; 13(22 Pt 1):6842-9. PubMed ID: 17982121
[TBL] [Abstract][Full Text] [Related]
11. Improvement of sensitivity to platinum compound with siRNA knockdown of upregulated genes in platinum complex-resistant ovarian cancer cells in vitro.
Yanagie H; Hisa T; Ogata A; Miyazaki A; Nonaka Y; Nishihira T; Osada I; Sairennji T; Sugiyama H; Furuya Y; Kidani Y; Takamoto S; Takahashi H; Eriguchi M
Biomed Pharmacother; 2009 Sep; 63(8):553-60. PubMed ID: 18571892
[TBL] [Abstract][Full Text] [Related]
12. [Expression of nuclear autoantigenic sperm protein in platinum resistance ovarian cancer cell clones].
Wang HX; Tan Y
Zhonghua Yi Xue Za Zhi; 2010 Jan; 90(1):61-3. PubMed ID: 20356529
[TBL] [Abstract][Full Text] [Related]
13. Absence of Bcl-xL down-regulation in response to cisplatin is associated with chemoresistance in ovarian carcinoma cells.
Villedieu M; Louis MH; Dutoit S; Brotin E; Lincet H; Duigou F; Staedel C; Gauduchon P; Poulain L
Gynecol Oncol; 2007 Apr; 105(1):31-44. PubMed ID: 17275076
[TBL] [Abstract][Full Text] [Related]
14. Proteomic studies of early-stage and advanced ovarian cancer patients.
Wang J; Zhang X; Ge X; Guo H; Xiong G; Zhu Y
Gynecol Oncol; 2008 Oct; 111(1):111-9. PubMed ID: 18703221
[TBL] [Abstract][Full Text] [Related]
15. Identification of genes whose expression is associated with cisplatin resistance in human ovarian carcinoma cells.
Cheng TC; Manorek G; Samimi G; Lin X; Berry CC; Howell SB
Cancer Chemother Pharmacol; 2006 Sep; 58(3):384-95. PubMed ID: 16404635
[TBL] [Abstract][Full Text] [Related]
16. Ankyrin repeat domain 1, ANKRD1, a novel determinant of cisplatin sensitivity expressed in ovarian cancer.
Scurr LL; Guminski AD; Chiew YE; Balleine RL; Sharma R; Lei Y; Pryor K; Wain GV; Brand A; Byth K; Kennedy C; Rizos H; Harnett PR; deFazio A
Clin Cancer Res; 2008 Nov; 14(21):6924-32. PubMed ID: 18980987
[TBL] [Abstract][Full Text] [Related]
17. Quantitative differences in protein expression between cisplatin sensitive C0C1 ovarian carcinoma cells and cisplatin resistant C0C1/DDP cells.
Wang HX; Sun W; Li HL; Zhang WY
Chin Med J (Engl); 2009 Apr; 122(7):865-9. PubMed ID: 19493403
[No Abstract] [Full Text] [Related]
18. Oxaliplatin induces drug resistance more rapidly than cisplatin in H69 small cell lung cancer cells.
Stordal BK; Davey MW; Davey RA
Cancer Chemother Pharmacol; 2006 Aug; 58(2):256-65. PubMed ID: 16283310
[TBL] [Abstract][Full Text] [Related]
19. Platinum(IV) complex with adamantylamine overcomes intrinsic resistance to cisplatin in ovarian cancer cells.
Horváth V; Blanárová O; Svihálková-Sindlerová L; Soucek K; Hofmanová J; Sova P; Kroutil A; Fedorocko P; Kozubík A
Gynecol Oncol; 2006 Jul; 102(1):32-40. PubMed ID: 16364413
[TBL] [Abstract][Full Text] [Related]
20. The homeobox gene BARX2 can modulate cisplatin sensitivity in human epithelial ovarian cancer.
Sellar GC; Watt KP; Li L; Nelkin BD; Rabiasz GJ; Porteous DJ; Smyth JF; Gabra H
Int J Oncol; 2002 Nov; 21(5):929-33. PubMed ID: 12370737
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
